Development and in vitro efficacy of novel MMP2 and MMP9 specific doxorubicin albumin conjugates - PubMed (original) (raw)
Development and in vitro efficacy of novel MMP2 and MMP9 specific doxorubicin albumin conjugates
F Kratz et al. Bioorg Med Chem Lett. 2001.
Abstract
Two doxorubicin albumin conjugates (A-DP1 and A-DP2), which differ in their substrate specificity for the matrix metalloproteinases MMP2 and MMP9, were prepared by binding maleimide doxorubicin peptide derivatives to the cysteine-34 position of human serum albumin. The incorporated octapeptide, Gly-Pro-Gln-Arg-Ile-Ala-Gly-Gln, in A-DP2 is not cleaved by activated MMP2 and MMP9 in contrast to Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln incorporated in A-DP1 that is cleaved efficiently by activated MMP2 and MMP9 liberating a doxorubicin tetrapeptide. A-DP1 showed antiproliferative activity in a murine renal cell carcinoma line in the low micromolar range (IC(50) value approximately 0.2 microM).
Similar articles
- A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2.
Mansour AM, Drevs J, Esser N, Hamada FM, Badary OA, Unger C, Fichtner I, Kratz F. Mansour AM, et al. Cancer Res. 2003 Jul 15;63(14):4062-6. Cancer Res. 2003. PMID: 12874007 - Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
Schmid B, Chung DE, Warnecke A, Fichtner I, Kratz F. Schmid B, et al. Bioconjug Chem. 2007 May-Jun;18(3):702-16. doi: 10.1021/bc0602735. Epub 2007 Mar 23. Bioconjug Chem. 2007. PMID: 17378599 - Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen.
Kratz F, Mansour A, Soltau J, Warnecke A, Fichtner I, Unger C, Drevs J. Kratz F, et al. Arch Pharm (Weinheim). 2005 Oct;338(10):462-72. doi: 10.1002/ardp.200500130. Arch Pharm (Weinheim). 2005. PMID: 16211657 - Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound.
Kratz F, Warnecke A, Scheuermann K, Stockmar C, Schwab J, Lazar P, Drückes P, Esser N, Drevs J, Rognan D, Bissantz C, Hinderling C, Folkers G, Fichtner I, Unger C. Kratz F, et al. J Med Chem. 2002 Dec 5;45(25):5523-33. doi: 10.1021/jm020276c. J Med Chem. 2002. PMID: 12459020 - The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
Garsky VM, Lumma PK, Feng DM, Wai J, Ramjit HG, Sardana MK, Oliff A, Jones RE, DeFeo-Jones D, Freidinger RM. Garsky VM, et al. J Med Chem. 2001 Nov 22;44(24):4216-24. doi: 10.1021/jm0101996. J Med Chem. 2001. PMID: 11708923
Cited by
- Curcumin-Loaded Hybrid Nanoparticles: Microchannel-Based Preparation and Antitumor Activity in a Mouse Model.
Hong W, Gao Y, Lou B, Ying S, Wu W, Ji X, Yu N, Jiao Y, Wang H, Zhou X, Li A, Guo F, Yang G. Hong W, et al. Int J Nanomedicine. 2021 Jun 17;16:4147-4159. doi: 10.2147/IJN.S303829. eCollection 2021. Int J Nanomedicine. 2021. PMID: 34168445 Free PMC article. - Tumour endoproteases: the cutting edge of cancer drug delivery?
Atkinson JM, Siller CS, Gill JH. Atkinson JM, et al. Br J Pharmacol. 2008 Apr;153(7):1344-52. doi: 10.1038/sj.bjp.0707657. Epub 2008 Jan 21. Br J Pharmacol. 2008. PMID: 18204490 Free PMC article. Review. - Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.
Isaacson KJ, Martin Jensen M, Subrahmanyam NB, Ghandehari H. Isaacson KJ, et al. J Control Release. 2017 Aug 10;259:62-75. doi: 10.1016/j.jconrel.2017.01.034. Epub 2017 Jan 31. J Control Release. 2017. PMID: 28153760 Free PMC article. Review. - Functional analysis of recombinant human serum albumin domains for pharmaceutical applications.
Matsushita S, Isima Y, Chuang VT, Watanabe H, Tanase S, Maruyama T, Otagiri M. Matsushita S, et al. Pharm Res. 2004 Oct;21(10):1924-32. doi: 10.1023/b:pham.0000045248.03337.0e. Pharm Res. 2004. PMID: 15553241 - The mirrored cationic peptide as miRNA vehicle for efficient lung cancer therapy.
Xu W, Du L, Yu L, Cen H, Lin F, Wang S, Ruan Z, Lin Z, Zhang X, Zhou N, Chang J, Yu X, Zhang L, Liang L. Xu W, et al. MedComm (2020). 2023 Jul 28;4(4):e273. doi: 10.1002/mco2.273. eCollection 2023 Aug. MedComm (2020). 2023. PMID: 37521428 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous